Elisabeth M. M. Gardiner

Nessuna posizione attualmente

Health Technology

Consumer Services

Profilo

Elisabeth M.
M.
Gardiner worked as a Director-Physiology Discovery at aTyr Pharma, Inc. and as a Principal at Kalypsys, Inc. She was also a Vice President-Discovery Biology at Kinnate Biopharma, Inc. from 2018 to 2020.
Gardiner served as VP-Translational Medicine & Patrick Simms at Aravive, Inc. from 2020 to 2022.
She holds a doctorate degree from the University of Wisconsin.

Precedenti posizioni note di Elisabeth M. M. Gardiner

Società	Posizione	Fine
ARAVIVE, INC.	Corporate Officer/Principal	01/04/2022
KINNATE BIOPHARMA INC.	Corporate Officer/Principal	01/06/2020
Kalypsys, Inc. Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA.	Corporate Officer/Principal	-
ATYR PHARMA, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Elisabeth M. M. Gardiner

Formazione di Elisabeth M. M. Gardiner

University of Wisconsin

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Elisabeth M. M. Gardiner

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
ATYR PHARMA, INC.	Health Technology
ARAVIVE, INC.	Health Technology

Aziende private	2
Kalypsys, Inc. Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA.	Health Technology
Kinnate Biopharma, Inc. Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.	Health Technology